Positive Correlation Between Symptoms and Circulating Motilin, Pancreatic Polypeptide and Gastrin Concentrations in Functional Bowel Disorders
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Adult Congenital Megacolon with Acute Fecal Obstruction and Diabetic Nephropathy: a Case Report
2726 EXPERIMENTAL AND THERAPEUTIC MEDICINE 18: 2726-2730, 2019 Adult congenital megacolon with acute fecal obstruction and diabetic nephropathy: A case report MINGYUAN ZHANG1,2 and KEFENG DING1 1Colorectal Surgery Department, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310000; 2Department of Gastrointestinal Surgery, Yinzhou Peoples' Hospital, Ningbo, Zhejiang 315000, P.R. China Received November 27, 2018; Accepted June 20, 2019 DOI: 10.3892/etm.2019.7852 Abstract. Megacolon is a congenital disorder. Adult congen- sufficient amount of bowel should be removed, particularly the ital megacolon (ACM), also known as adult Hirschsprung's aganglionic segment (2). The present study reports on a case of disease, is rare and frequently manifests as constipation. ACM a 56-year-old patient with ACM, fecal impaction and diabetic is caused by the absence of ganglion cells in the submucosa nephropathy. or myenteric plexus of the bowel. Most patients undergo treat- ment of megacolon at a young age, but certain patients cannot Case report be treated until they develop bowel obstruction in adulthood. Bowel obstruction in adults always occurs in complex clinical A 56-year-old male patient with a history of chronic constipa- situations and it is frequently combined with comorbidities, tion presented to the emergency department of Yinzhou including bowel tumors, volvulus, hernias, hypertension or Peoples' Hospital (Ningbo, China) in February 2018. The diabetes mellitus. Surgical intervention is always required in patient had experienced vague abdominal distention for such cases. To avoid recurrence, a sufficient amount of bowel several days. Prior to admission, chronic bowel obstruction should be removed, particularly the aganglionic segment. -
Regulation of the Gastrin Promoter by Epidermal Growth Factor and Neuropeptides JUANITA M
Proc. Nati. Acad. Sci. USA Vol. 86, pp. 3036-3040, May 1989 Biochemistry Regulation of the gastrin promoter by epidermal growth factor and neuropeptides JUANITA M. GODLEY AND STEPHEN J. BRAND Gastrointestinal Unit, Department of Medicine, Harvard Medical School, Massachusetts General Hospital, Boston, MA 02114 Communicated by Kurt J. Isselbacher, December 30, 1988 ABSTRACT The regulation of gastrin gene transcription gastrin secretion (12, 13), the effect of GRP on gastrin gene was studied in GH4 pituitary cells transfected with constructs expression has not been reported. Antral G cells are also comprised of the first exon of the human gastrin gene and inhibited by the paracrine release of somatostatin from various lengths of 5' regulatory sequences ligated upstream of adjacent antral D cells (14), and local release of somatostatin the reporter gene chloramphenicol acetyltransferase. Gastrin inhibits gastrin gene expression as well as gastrin secretion reporter gene activity in GH4 cells was equal to the activity of (15). a reporter gene transcribed from the endogenously expressed In contrast to the detailed studies on gastrin secretion, the growth hormone promoter. The effect of a variety of peptides regulation of gastrin gene expression has not been well on gastrin gene transcription including epidermal growth investigated. The cellular mechanisms controlling gastrin factor (normally present in the gastric lumen), gastrin- secretion have been analyzed using isolated primary G cells releasing peptide, vasoactive intestinal peptide, and somato- (12, 13); however, the limited viability of these cells has statin (present in gastric nerves) was assessed. Epidermal precluded their use in studying the regulation of gastrin gene growth factor increased the rate ofgastrin transcription almost transcription using DNA transfection techniques. -
Adipokines in Breast Milk: an Update Gönül Çatlı1, Nihal Olgaç Dündar2, Bumin Nuri Dündar3
J Clin Res Pediatr Endocrinol 2014;6(4):192-201 DO I: 10.4274/jcrpe.1531 Review Adipokines in Breast Milk: An Update Gönül Çatlı1, Nihal Olgaç Dündar2, Bumin Nuri Dündar3 1Tepecik Training and Research Hospital, Clinic of Pediatric Endocrinology, İzmir, Turkey 2Katip Çelebi University Faculty of Medicine, Department of Pediatric Neurology, İzmir, Turkey 3Katip Çelebi University Faculty of Medicine, Department of Pediatric Endocrinology, İzmir, Turkey Introduction Human breast milk comprises a variety of nutrients, cytokines, peptides, enzymes, cells, immunoglobulins, proteins and steroids specially suited to meet the needs of newborn infants (1,2). Breast milk has benefits on preventing metabolic disorders and chronic diseases and is referred to as “functional food” due to its roles other than nutrition (1,2). It contains 87-90% water and is the main source of water for newborns (3,4,5). In addition, several peptide/protein hormones have recently been identified in human breast milk, including leptin, adiponectin, resistin, obestatin, nesfatin, irisin, adropin, copeptin, ghrelin, pituitary adenylate cyclase-activating polypeptide, apelins, motilin and cholecystokinin (6,7). These breast milk hormones may transiently regulate the activities of various tissues, including endocrine organs until the endocrine system of the neonate begins to function (6). Some of these peptides are secreted in biologically active forms (3). Leptin, ghrelin, insulin, adiponectin, obestatin, resistin, epidermal growth factor, platelet-derived growth factor and insulin-like growth factor 1 are bioactive substances that play roles in energy intake and regulation of body composition (3). However, functions of some ABS TRACT of these peptides in neonatal development are still unknown Epidemiological surveys indicate that nutrition in infancy is implicated in the (4). -
Adrenocorticotrophic and Melanocyte-Stimulating Peptides in the Human Pituitary by ALEXANDER P
Biochem. J. (1974) 139, 593-602 593 Printed in Great Britain Adrenocorticotrophic and Melanocyte-Stimulating Peptides in the Human Pituitary By ALEXANDER P. SCOTT and PHILIP J. LOWRY* Department ofChemical Pathology, St. Bartholomew's Hospital, London EC1A 7BE, U.K. and CIBA Laboratories, Horsham, Sussex RH12 4AB, U.K. (Received 7 December 1973) The adrenocorticotrophic and melanocyte-stimulating peptides of the human pituitary were investigated by means of radioimmunoassay, bioassay and physicochemical pro- cedures. Substantial amounts of adrenocorticotrophin and a peptide resembling /8-lipotrophin were identified in pituitary extracts, but a-melanocyte-stimulating hormone, ,B-melanocyte-stimulating hormone and corticotrophin-like intermediate lobe peptide, which have been identified in thepars intermedia ofpituitaries from other vertebrates, were not found. The absence of fJ-melanocyte-stimulating hormone appears to contradict previous chemical and radioimmunological studies. Our results suggest, however, that it is not a natural pituitary peptide but an artefact formed by enzymic degradation of ,6-lipotrophin during extraction. Melanocyte-stimulating and corticotrophic pep- extraction of human pituitaries for growth hormone tides have been identified in the pituitaries of all (Dixon, 1960). Its stucture was determined by Harris vertebrate species studied, and several have been (1959) and shown to be similar to ,B-MSH isolated isolated and characterized. They belong to two from other species, except for the presence of an structually related classes, namely those related to extra four amino acids at the N-terminus. The adrenocorticotrophin (ACTH) including ACTH, presence of sufficient amounts of 8-MSH in human a-melanocyte-stimulating hormone (a-MSH) and pituitaries to account alone for the bulk of the 'corticotrophin-like intermediate lobepeptide' ACTH melanocyte-stimulating activity in the pituitary (18-39) peptide (CLIP), and others related to fi- extracts was shown by radioimmunoassay (Abe et al., melanocyte-stimulating hormone (,B-MSH) including 1967b). -
Searching for Novel Peptide Hormones in the Human Genome Olivier Mirabeau
Searching for novel peptide hormones in the human genome Olivier Mirabeau To cite this version: Olivier Mirabeau. Searching for novel peptide hormones in the human genome. Life Sciences [q-bio]. Université Montpellier II - Sciences et Techniques du Languedoc, 2008. English. tel-00340710 HAL Id: tel-00340710 https://tel.archives-ouvertes.fr/tel-00340710 Submitted on 21 Nov 2008 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. UNIVERSITE MONTPELLIER II SCIENCES ET TECHNIQUES DU LANGUEDOC THESE pour obtenir le grade de DOCTEUR DE L'UNIVERSITE MONTPELLIER II Discipline : Biologie Informatique Ecole Doctorale : Sciences chimiques et biologiques pour la santé Formation doctorale : Biologie-Santé Recherche de nouvelles hormones peptidiques codées par le génome humain par Olivier Mirabeau présentée et soutenue publiquement le 30 janvier 2008 JURY M. Hubert Vaudry Rapporteur M. Jean-Philippe Vert Rapporteur Mme Nadia Rosenthal Examinatrice M. Jean Martinez Président M. Olivier Gascuel Directeur M. Cornelius Gross Examinateur Résumé Résumé Cette thèse porte sur la découverte de gènes humains non caractérisés codant pour des précurseurs à hormones peptidiques. Les hormones peptidiques (PH) ont un rôle important dans la plupart des processus physiologiques du corps humain. -
Expression and Localization of Gastrin Messenger RNA and Peptide in Spermatogenic Cells
Expression and localization of gastrin messenger RNA and peptide in spermatogenic cells. M Schalling, … , T Hökfelt, J F Rehfeld J Clin Invest. 1990;86(2):660-669. https://doi.org/10.1172/JCI114758. Research Article In previous studies we have shown that the gene encoding cholecystokinin (CCK) is expressed in spermatogenic cells of several mammalian species. In the present study we show that a gene homologous to the CCK-related hormone, gastrin, is expressed in the human testis. The mRNA hybridizing to a human gastrin cDNA probe in the human testis was of the same size (0.7 kb) as gastrin mRNA in the human antrum. By in situ hybridization the gastrinlike mRNA was localized to seminiferous tubules. Immunocytochemical staining of human testis revealed gastrinlike peptides in the seminiferous tubules primarily at a position corresponding to spermatids and spermatozoa. In ejaculated spermatozoa gastrinlike immunoreactivity was localized to the acrosome. Acrosomal localization could also be shown in spermatids with electron microscopy. Extracts of the human testis contained significant amounts of progastrin, but no bioactive amidated gastrins. In contrast, ejaculated sperm contained mature carboxyamidated gastrin 34 and gastrin 17. The concentration of gastrin in ejaculated human spermatozoa varied considerably between individuals. We suggest that amidated gastrin (in humans) and CCK (in other mammals) are released during the acrosome reaction and that they may be important for fertilization. Find the latest version: https://jci.me/114758/pdf Expression and Localization of Gastrin Messenger RNA and Peptide in Spermatogenic Cells Martin Schalling,* Hhkan Persson,t Markku Pelto-Huikko,*9 Lars Odum,1I Peter Ekman,I Christer Gottlieb,** Tomas Hokfelt,* and Jens F. -
Etiology and Management of Toxic Megacolon with Human
GASTROENTEROLOGY 1994;107:898-883 Etiology and Management of Toxic Megacolon in Patients With Human lmmunodeficiency Virus Infection LAURENT BEAUGERIE,* YANN NG&* FRANCOIS GOUJARD,’ SHAHIN GHARAKHANIAN,§ FRANCK CARBONNEL,* JACQUELINE LUBOINSKI, ” MICHEL MALAFOSSE,’ WILLY ROZENBAUM,§ and YVES LE QUINTREC* Departments of *Gastroenterology, ‘Surgery, %fectious Diseases, and llPathology, Hdpital Rothschild, Paris, France We report six cases of toxic megacolon in patients with megacolon, we opted for nonsurgical treatment of colonic human immunodeficiency virus (HIV). One case, at an decompression and anti-CMV treatment with a favorable early stage of HIV infection, mimicked a severe attack short-term outcome. of Crohn’s disease, with a negative search for infec- tious agents. Subtotal colectomy was successfully per- Case Report formed with an uneventful postoperative course. The All of the cases of toxic megacolon in patients with five other cases concerned patients with acquired im- HIV seen at Rothschild Hospital between 1988 and 1992 were munodeficiency syndrome at a late stage of immunode- reviewed. During this period, 2430 patients were seen in the ficiency. They were related to Clostridium ditTcile or hospital for HIV infection. Diagnostic criteria for toxic mega- cytomegalovirus (CMV) intestinal infection in two and colon were defined as follows: (1) histologically proven colitis; three patients, respectively. One case of CMV colitis (2) radiological dilatation of the transverse colon on x-ray film presented macroscopically and histologically as pseu- of the abdomen with a colonic diameter above 6 cm at the domembranous colitis. Emergency subtotal colectomy, point of maximum dilatation’*; and (3) evidence of at least performed in the first four patients with acquired immu- two of these following signs’: tachycardia greater than 100 nodeficiency syndrome was followed by a fatal postop beats per minute, body temperature >38.6”C, leukocytosis erative outcome. -
Toxic Megacolon with Colonic Ischemia Masquerading As Diabetic Ketoacidosis: a Case Report F
Saudi Journal of Medical and Pharmaceutical Sciences Abbreviated Key Title: Saudi J Med Pharm Sci ISSN 2413-4929 (Print) |ISSN 2413-4910 (Online) Scholars Middle East Publishers, Dubai, United Arab Emirates Journal homepage: https://saudijournals.com/sjmps Case Report Toxic Megacolon with Colonic Ischemia Masquerading as Diabetic Ketoacidosis: A Case Report F. Mansouri* Department of Pediatrics, King Abdulaziz University, Jeddah, Saudi Arabia DOI: 10.36348/sjmps.2020.v06i01.010 | Received: 03.01.2020 | Accepted: 15.01.2020 | Published: 22.01.2020 *Corresponding author: Mansouri F Abstract A previously healthy 12-year-old boy presented with abdominal pain and clinical and laboratory features highly suggestive of diabetic ketoacidosis. When his blood glucose plummeted and his urinary ketones disappeared within the first hour of insulin therapy, while his abdominal pain, acidosis and hemodynamic status failed to improve despite vigorous fluid resuscitation, the diagnosis of diabetic ketoacidosis was questioned. At laparotomy, gangrenous, hugely dilated large bowel was found, requiring a subtotal colectomy from the cecum to the sigmoid colon; leaving the patient with an ileostomy. The child survived a complicated postoperative course and is currently doing well. Keywords: Ischemic bowel, toxic megacolon, diabetic ketoacidosis. Copyright @ 2020: This is an open-access article distributed under the terms of the Creative Commons Attribution license which permits unrestricted use, distribution, and reproduction in any medium for non-commercial use (NonCommercial, or CC-BY-NC) provided the original author and source are credited. NTRODUCTION never been on any treatment and had been incompliant I with dietary modifications. 4 days prior to presentation, Twenty percent to 40% of children with newly he had progressively worsening episodes of abdominal diagnosed insulin-dependent (type-I) diabetes mellitus pain, mainly in his right lower quadrant (RLQ). -
Megacolon Toxic of Idiophatic Origin: Case Report
DOI: http://dx.doi.org/10.22516/25007440.256 Case report Megacolon toxic of idiophatic origin: case report Sergio Andrés Siado,1 Héctor Conrado Jiménez,2 Carlos Mauricio Martínez Montalvo.3 1 General Surgeon at Clinica Belo Horizonte and Abstract Clinica Medilaser in Neiva, Huila, Colombia 2 Epidemiologist and second year resident in general Toxic megacolon is a pathology whose mortality rate is over 80%. A progressive inflammatory process com- surgery at Universidad Surcolombiana and the promises the colon wall, and secondary dilation of the intestinal lumen occurs due to inflammatory or in- Hospital Universitario Hernando Moncaleano fectious processes. Its clinical presentation is bizarre. but the basic pillars for management are opportune Perdomo in Neiva, Huila, Colombia 3 General Practitioner at the Universidad diagnosis and adequate medical management with antibiotics, water resuscitation, and metabolic correction. Surcolombiana in Neiva, Huila, Colombia If necessary, effective surgical management can prevent the development of complications that worsen the disease and the prognosis of a patient. In this article we present the case of a patient who died after deve- Corresponding author: Carlos Mauricio Martinez Montalvo. [email protected] loping septic shock secondary to toxic megacolon. Cholangitis grade III was suspected, but discarded after ultrasonography, and this resulted in generated distortions in approach and initial management. Due to clinical ......................................... deterioration and abdominal distension, the patient underwent diagnostic laparoscopy which revealed severe Received: 08-08-17 Accepted: 13-04-18 ischemic compromise of the entire colon but without involvement of the small intestine. For this reason, a total colectomy was performed. The pathology report and clinical history ruled out ulcerative colitis or Crohn’s disease which confirmed the diagnosis of toxic megacolon. -
Supplementary Table 1. Clinico-Pathologic Features of Patients with Pancreatic Neuroendocrine Tumors Associated with Cushing’S Syndrome
Supplementary Table 1. Clinico-pathologic features of patients with pancreatic neuroendocrine tumors associated with Cushing’s syndrome. Review of the English/Spanish literature. Other hormones Age of Cortisol Other hormones Other ACTH Size (ICH or assay) ENETS Follow- Time Year Author Sex CS onset level (Blood syndromes or Site MET Type AH level (cm) corticotrophic Stage up (months) (years) (µg/dl) detection) NF other differentiation 1 1 1946 Crooke F 28 uk uk none no 4.5 H liver/peritoneum NET uk uk yes IV DOD 6 2 1956 Rosenberg 2 F 40 uk 92 none no 10 B liver NET uk uk yes IV PD 3 & p 3 1959 Balls F 36 uk elevated insulin Insulinoma 20 B liver/LNl/lung NET uk uk yes IV DOD 1 4 & 4 1962 Meador F 47 13~ elevated none no uk T liver/spleen NET ACTH uk yes IV uk 5 1963 Liddle5 uk uk uk elevated uk uk uk uk uk NET ACTH uk uk uk uk 6 1964 Hallwright6 F 32 uk uk none no large H LN/liver NET ACTH, MSH uk yes IV DOD 24 7 1965 Marks7 M 43 uk elevated insulin insulinomas 1.8 T liver NET uk uk yes IV DOD 7 8 1965 Sayle8 F 62 uk uk none carcinoidb 4 H LN/liver NET uk uk yes IV DOD 6 9 1965 Sayle8 F 15 uk uk none no 4 T no NET ACTH uk yes IIa DOD 5 9 b mesentery/ 10 1965 Geokas M 59 uk uk gastrin ZES large T NET uk uk yes IV DOD 2 LN/pleural/bone 11 1965 Law10 F 35 1.2 ∞ 91 gastrin ZESs uk B LN/liver NET ACTH, MSH gastrin yes IV PD 12 1967 Burkinshaw11 M 2 uk 72 none no large T no NET uk uk no uk AFD 12 13 1968 Uei12 F 9 uk uk none ZESs 7 T liver NET ACTH uk yes IV DOD 8 13 PTH, ADH, b gastrin, 14 1968 O'Neal F 52 13~ uk ZES uk T LN/liver/bone NET -
Effect of Atropine on Vagal Release of Gastrin and Pancreatic Polypeptide
Effect of Atropine on Vagal Release of Gastrin and Pancreatic Polypeptide MARK FELDMAN, CHARLES T. RICHARDSON, IAN L. TAYLOR, and JOHN H. WALSH, Departments of Internal Medicine, Veterans Administration Hospital, Dallas, Texas 75216; University of California at Los Angeles Health Science Center, Los Angeles, California 90093; and The University of Texas Health Science Center at Dallas, Southwestern Medical School, Dallas, Texas 75235 A B S TRA C T We studied the effect of several doses of the rise in serum gastrin concentration induced by in- atropine on the serum gastrin and pancreatic poly- sulin hypoglycemia was further increased by atropine peptide responses to vagal stimulation in healthy premedication (1). In addition, several workers have human subjects. Vagal stimulation was induced by shown that atropine increases the serum gastrin con- sham feeding. To eliminate the effect of gastric acidity centration after an eaten meal (2-4). These observa- on gastrin release, gastric pH was held constant (pH 5) tions, together with the fact that basal and postprandial and acid secretion was measured by intragastric titra- gastrin levels rise after vagotomy (5-7), have led to tion. Although a small dose of atropine (2.3 ,ug/kg) speculation that the vagus nerve can inhibit, as well as significantly inhibited the acid secretory response and stimulate, gastrin release. completely abolished the pancreatic polypeptide re- For several reasons, however, none of these observa- sponse to sham feeding, this dose of atropine signifi- tions proves that the vagus nerve actually inhibits cantly enhanced the gastrin response. Higher atropine gastrin release under normal circumstances. First, doses (7.0 and 21.0,g/kg) had effects on gastrin and studies using insulin hypoglycemia as a vagal stimulant pancreatic polypeptide release which were similar to must be interpreted with caution because there is the 2.3-pAg/kg dose. -
Identification of Neuropeptide Receptors Expressed By
RESEARCH ARTICLE Identification of Neuropeptide Receptors Expressed by Melanin-Concentrating Hormone Neurons Gregory S. Parks,1,2 Lien Wang,1 Zhiwei Wang,1 and Olivier Civelli1,2,3* 1Department of Pharmacology, University of California Irvine, Irvine, California 92697 2Department of Developmental and Cell Biology, University of California Irvine, Irvine, California 92697 3Department of Pharmaceutical Sciences, University of California Irvine, Irvine, California 92697 ABSTRACT the MCH system or demonstrated high expression lev- Melanin-concentrating hormone (MCH) is a 19-amino- els in the LH and ZI, were tested to determine whether acid cyclic neuropeptide that acts in rodents via the they are expressed by MCH neurons. Overall, 11 neuro- MCH receptor 1 (MCHR1) to regulate a wide variety of peptide receptors were found to exhibit significant physiological functions. MCH is produced by a distinct colocalization with MCH neurons: nociceptin/orphanin population of neurons located in the lateral hypothala- FQ opioid receptor (NOP), MCHR1, both orexin recep- mus (LH) and zona incerta (ZI), but MCHR1 mRNA is tors (ORX), somatostatin receptors 1 and 2 (SSTR1, widely expressed throughout the brain. The physiologi- SSTR2), kisspeptin recepotor (KissR1), neurotensin cal responses and behaviors regulated by the MCH sys- receptor 1 (NTSR1), neuropeptide S receptor (NPSR), tem have been investigated, but less is known about cholecystokinin receptor A (CCKAR), and the j-opioid how MCH neurons are regulated. The effects of most receptor (KOR). Among these receptors, six have never classical neurotransmitters on MCH neurons have been before been linked to the MCH system. Surprisingly, studied, but those of most neuropeptides are poorly several receptors thought to regulate MCH neurons dis- understood.